Table 4.

Comparison of safety in LTFU and patients with SVR assessment

Parameter	LTFU, n=509	Patients with SVR assessment, n=18,354	p
Therapy course, n (%)
According to schedule	432 (84.9)	18,002 (98.1)	<0.0001
Discontinuation	56 (11)	227 (1.2)
Modification	6 (1.2)	105 (0.6)
No data	15 (2.9)	20 (0.1)
Patients with at least one AE, n (%)	86 (16.9)	3085 (16.8)	0.95
Treatment discontinuation due to AE in relation to all cases of discontinuation, n/n (%)	19/56 (33.9)	76/227 (33.4)	0.949
Serious adverse events, n (%)	15 (2.9)	144 (0.8)	<0.0001

Abbreviations: AE adverse event, LTFU loss to follow-up, SVR sustained virological response